三博脑科(301293) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥393,473,847.68, representing a 16.78% increase compared to ¥336,930,401.64 in the same period last year[5] - Net profit attributable to shareholders was ¥38,313,576.61, up 14.56% from ¥33,444,602.02 year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 19.40% to ¥38,606,346.69 from ¥32,333,153.81 in the previous year[5] - Basic and diluted earnings per share were both ¥0.19, an increase of 18.75% compared to ¥0.16 in the previous year[5] - Total operating revenue for the current period reached ¥393,473,847.68, an increase of 16.7% compared to ¥336,930,401.64 in the previous period[18] - Net profit for the current period was ¥41,055,460.56, representing a growth of 5.3% from ¥38,749,465.53 in the previous period[19] - The net profit attributable to the parent company was ¥38,313,576.61, an increase of 14.0% compared to ¥33,444,602.02 in the previous period[19] - Basic earnings per share for the current period was ¥0.19, up from ¥0.16 in the previous period[19] Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 99.52%, dropping to ¥136,584.64 from ¥28,472,761.60 in the same period last year[5] - The company's cash and cash equivalents decreased from 708,348,100.12 CNY to 616,263,821.89 CNY, a decline of approximately 13.00%[15] - The total current assets decreased from 980,464,070.04 CNY to 887,378,992.30 CNY, a decline of approximately 9.46%[15] - The company's fixed assets decreased slightly from 606,595,212.30 CNY to 605,101,855.98 CNY[15] - Operating cash flow net amount was 136,584.64, a significant decrease from 28,472,761.60 in the previous period[22] - Cash inflow from operating activities totaled 404,525,922.79, compared to 375,826,914.79 last year, reflecting an increase of approximately 7.5%[22] - Cash outflow from operating activities was 404,389,338.15, up from 347,354,153.19, indicating a rise of about 16.4%[22] - The net increase in cash and cash equivalents was -92,084,278.23, contrasting with an increase of 324,686,913.70 in the previous period[23] - The ending balance of cash and cash equivalents was 468,314,039.97, down from 1,146,809,266.74 last year[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 37,673[10] - TBP 3Doctors (HK) Limited holds 15.70% of shares, totaling 32,330,025 shares[10] - Zhang Yang, a domestic individual, holds 10.59% of shares, totaling 21,815,703 shares[10] - The total number of restricted shares at the end of the period is 45,041,295 shares, with no changes during the reporting period[12] - The company has a significant shareholder structure with Zhang Yang, Yu Chunjiang, Shi Xiangen, and Luan Guoming acting as concerted actors, collectively controlling the company[11] - The company has no preferred shareholders or changes in preferred shareholder structure during the reporting period[11] Liabilities and Equity - Total assets at the end of the reporting period were ¥3,589,563,529.09, reflecting a 1.65% increase from ¥3,531,288,628.12 at the end of the previous year[5] - Total liabilities increased to ¥918,604,788.64, compared to ¥901,385,348.22 in the previous period[17] - Shareholders' equity attributable to the parent company increased by 1.67% to ¥2,336,754,598.79 from ¥2,298,441,022.18 at the end of the previous year[5] - The total equity attributable to the parent company was ¥2,336,754,598.79, an increase from ¥2,298,441,022.18 in the previous period[17] Operational Changes - The contribution to revenue growth was primarily due to the consolidation of Dahuang Guoze into the group on November 30, 2024[9] - The decrease in net cash flow from operating activities was attributed to changes in medical insurance prepayment and increased cash payments for goods and services[9] - The company received government subsidies amounting to ¥399,818.20, which were closely related to its normal business operations[7] - Long-term borrowings increased to ¥196,604,871.23, compared to ¥135,775,842.49 in the previous period, indicating a strategic move towards leveraging for growth[18] - The company established Sanbo Brain Science (Beijing) Health Industry Technology Co., Ltd. with a registered capital of 100 million CNY, holding a 100% stake[13] Accounting and Reporting - The company plans to implement new accounting standards starting in 2025, which may impact financial reporting[24] - The first quarter report was not audited, indicating a potential area for further scrutiny[24]